{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:27:59Z","timestamp":1794288479067,"version":"4.9.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["BRF1-045-2565"],"award-info":[{"award-number":["BRF1-045-2565"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019274","name":"Ramathibodi Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.antiviral.2022.105370","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T11:28:01Z","timestamp":1656329281000},"page":"105370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera"],"prefix":"10.1016","volume":"204","author":[{"given":"Chotiwat","family":"Seephetdee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanit","family":"Bhukhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattawut","family":"Buasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puttipatch","family":"Leelukkanaveera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pat","family":"Lerdwattanasombat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwimon","family":"Manopwisedjaroen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nut","family":"Phueakphud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakonwan","family":"Kuhaudomlarp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Olmedillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica Ollmann","family":"Saphire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunee","family":"Thitithanyanont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suradej","family":"Hongeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6070-1843","authenticated-orcid":false,"given":"Patompon","family":"Wongtrakoongate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2022.105370_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10020180","article-title":"Low neutralizing antibody titers against the Mu variant of SARS-CoV-2 in 31 BNT162b2 vaccinated individuals in Colombia","volume":"10","author":"\u00c1lvarez-D\u00edaz","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.antiviral.2022.105370_bib2","article-title":"SARS-CoV-2 spike conformation determines plasma neutralizing activity","author":"Bowen","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.antiviral.2022.105370_bib3","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2022.105370_bib4","doi-asserted-by":"crossref","unstructured":"Carnell George, W. et al. SARS-CoV-2 spike protein stabilized in the closed state induces potent neutralizing responses. J. Virol. 95, e00203-00221, doi:10.1128\/JVI.00203-21.","DOI":"10.1128\/JVI.00203-21"},{"key":"10.1016\/j.antiviral.2022.105370_bib5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.str.2021.05.014","article-title":"Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies","volume":"29","author":"Cerutti","year":"2021","journal-title":"Structure"},{"key":"10.1016\/j.antiviral.2022.105370_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.167332","article-title":"Glycosylation and serological reactivity of an expression-enhanced SARS-CoV-2 viral spike Mimetic","volume":"434","author":"Chawla","year":"2022","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.antiviral.2022.105370_bib7","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S2666-5247(21)00280-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"3","author":"Chen","year":"2022","journal-title":"The Lancet Microbe"},{"key":"10.1016\/j.antiviral.2022.105370_bib8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2022.105370_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/v12050513","article-title":"Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays","volume":"12","author":"Crawford","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2022.105370_bib10","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.cell.2021.02.032","article-title":"The antigenic anatomy of SARS-CoV-2 receptor binding domain","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2022.105370_bib11","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","article-title":"Antibody evasion by the P.1 strain of SARS-CoV-2","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2022.105370_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2021.06.018","article-title":"COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge","volume":"54","author":"DiPiazza","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2022.105370_bib13","article-title":"In contrast to TH2-biased approaches, TH1 COVID-19 vaccines protect Syrian hamsters from severe disease in the absence of dexamethasone-treatable vaccine-associated enhanced respiratory pathology","author":"Ebenig","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.antiviral.2022.105370_bib14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1126\/science.abn1900","article-title":"Stopping pandemics before they start: lessons learned from SARS-CoV-2","volume":"375","author":"Edwards","year":"2022","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.antiviral.2022.105370_bib15","article-title":"mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron","author":"Gagne","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.antiviral.2022.105370_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev-med-121217-094234","article-title":"Structure-based vaccine antigen design","volume":"70","author":"Graham","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.antiviral.2022.105370_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010248","article-title":"A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy","volume":"18","author":"Greaney","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2022.105370_bib18","series-title":"SARS-CoV-2 Variants, Spike Mutations and Immune Escape","author":"Harvey","year":"2021"},{"key":"10.1016\/j.antiviral.2022.105370_bib19","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1126\/science.abh2315","article-title":"Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study","volume":"374","author":"Hastie Kathryn","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2022.105370_bib20","article-title":"Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in na\u00efve hamsters compared to ancestral vaccine","author":"Hawman","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.antiviral.2022.105370_bib21","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.antiviral.2022.105370_bib22","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.vaccine.2022.01.043","article-title":"Phase I interim results of a phase I\/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452","volume":"40","author":"Janssen","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2022.105370_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41541-021-00324-5","article-title":"Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models","volume":"6","author":"Kalnin","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.antiviral.2022.105370_bib24","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2022.105370_bib25","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated VACCINE12","volume":"89","author":"Kim","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.antiviral.2022.105370_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110218","article-title":"The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance","volume":"38","author":"Kimura","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.antiviral.2022.105370_bib27","article-title":"Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis","volume":"8","author":"Kirchdoerfer","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2022.105370_bib28","article-title":"Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variants","author":"Lee","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.antiviral.2022.105370_bib29","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.abl8506","article-title":"Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants","volume":"374","author":"McCallum","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2022.105370_bib30","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1126\/science.abi7994","article-title":"SARS-CoV-2 immune evasion by the B.1.427\/B.1.429 variant of concern","volume":"373","author":"McCallum","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2022.105370_bib31","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1126\/science.abn8652","article-title":"Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement","volume":"375","author":"McCallum","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2022.105370_bib32","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1002\/jmv.27247","article-title":"A cluster of the new SARS-CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine","volume":"93","author":"Messali","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2022.105370_bib33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2022.105370_bib34","article-title":"Structure-based design of a highly stable, covalently-linked SARS-CoV-2 spike trimer with improved structural properties and immunogenicity","author":"Olmedillas","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.antiviral.2022.105370_bib35","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2022.105370_bib36","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2022.105370_bib37","article-title":"A computational dissection of spike protein of SARS-CoV-2 Omicron variant","author":"Rehman","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.antiviral.2022.105370_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9050498","article-title":"Mice immunized with the vaccine candidate HexaPro spike produce neutralizing antibodies against SARS-CoV-2","volume":"9","author":"Seephetdee","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.antiviral.2022.105370_bib39","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc2103740","article-title":"Neutralization of SARS-CoV-2 variants B.1.429 and B.1.351","volume":"384","author":"Shen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2022.105370_bib40","article-title":"SARS-CoV-2 lambda variant remains susceptible to neutralization by mRNA vaccine-elicited antibodies and convalescent serum","author":"Tada","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.antiviral.2022.105370_bib41","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1017\/S0950268821002430","article-title":"SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence","volume":"149","author":"Tatsi","year":"2021","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.antiviral.2022.105370_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2022.105370_bib43","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMc2114706","article-title":"Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum","volume":"385","author":"Uriu","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2022.105370_bib44","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2022.105370_bib45","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","article-title":"Engineering circular RNA for potent and stable translation in eukaryotic cells","volume":"9","author":"Wesselhoeft","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2022.105370_bib46","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","article-title":"Engineering circular RNA for potent and stable translation in eukaryotic cells","volume":"9","author":"Wesselhoeft","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2022.105370_bib47","article-title":"Mapping SARS-CoV-2 antigenic relationships and serological responses","author":"Wilks","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.antiviral.2022.105370_bib48","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2022.105370_bib49","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105370_bib50","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.cell.2020.09.018","article-title":"Molecular architecture of the SARS-CoV-2 virus","volume":"183","author":"Yao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2022.105370_bib51","article-title":"Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice","author":"Ying","year":"2022","journal-title":"bioRxiv"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222001395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222001395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:12:09Z","timestamp":1777497129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354222001395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":51,"alternative-id":["S0166354222001395"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105370","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105370"}}